Progyny, Inc. (NASDAQ:PGNY) Shares Purchased by Cercano Management LLC

Cercano Management LLC boosted its holdings in Progyny, Inc. (NASDAQ:PGNY) by 8.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 772,339 shares of the company’s stock after buying an additional 62,983 shares during the quarter. Progyny accounts for about 0.9% of Cercano Management LLC’s investment portfolio, making the stock its 28th largest position. Cercano Management LLC owned approximately 0.81% of Progyny worth $28,716,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in PGNY. RiverPark Advisors LLC grew its holdings in shares of Progyny by 54.0% in the 4th quarter. RiverPark Advisors LLC now owns 1,067 shares of the company’s stock worth $40,000 after acquiring an additional 374 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Progyny in the 3rd quarter worth $53,000. Parkside Financial Bank & Trust grew its holdings in shares of Progyny by 9.3% in the 4th quarter. Parkside Financial Bank & Trust now owns 3,096 shares of the company’s stock worth $115,000 after acquiring an additional 264 shares during the last quarter. CWM LLC grew its holdings in shares of Progyny by 16.1% in the 3rd quarter. CWM LLC now owns 3,490 shares of the company’s stock worth $119,000 after acquiring an additional 483 shares during the last quarter. Finally, Cetera Trust Company N.A acquired a new position in shares of Progyny in the 4th quarter worth $183,000. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Price Performance

PGNY traded down $0.46 during trading on Friday, reaching $32.04. 583,458 shares of the stock traded hands, compared to its average volume of 653,672. The stock has a market cap of $3.08 billion, a price-to-earnings ratio of 51.68, a price-to-earnings-growth ratio of 1.32 and a beta of 1.48. Progyny, Inc. has a fifty-two week low of $29.44 and a fifty-two week high of $44.95. The stock’s 50-day simple moving average is $35.84 and its two-hundred day simple moving average is $35.62.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Tuesday, February 27th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.04. The firm had revenue of $269.94 million during the quarter, compared to analysts’ expectations of $274.08 million. Progyny had a return on equity of 12.64% and a net margin of 5.70%. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.03 earnings per share. Research analysts anticipate that Progyny, Inc. will post 0.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Leerink Partnrs restated an “outperform” rating on shares of Progyny in a report on Monday, February 26th. SVB Leerink initiated coverage on Progyny in a research report on Monday, February 26th. They issued an “outperform” rating and a $49.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $48.00 target price on shares of Progyny in a research report on Wednesday, February 28th. KeyCorp decreased their target price on Progyny from $45.00 to $43.00 and set an “overweight” rating for the company in a research report on Wednesday, February 28th. Finally, Barclays initiated coverage on Progyny in a research report on Wednesday, January 3rd. They issued an “overweight” rating and a $48.00 target price for the company. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $48.30.

Insiders Place Their Bets

In other Progyny news, Chairman David J. Schlanger sold 20,000 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $38.50, for a total value of $770,000.00. Following the completion of the sale, the chairman now owns 86,312 shares of the company’s stock, valued at $3,323,012. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Progyny news, Chairman David J. Schlanger sold 20,000 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $38.50, for a total value of $770,000.00. Following the completion of the sale, the chairman now owns 86,312 shares of the company’s stock, valued at $3,323,012. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman David J. Schlanger sold 71,272 shares of the business’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $37.80, for a total value of $2,694,081.60. Following the completion of the sale, the chairman now directly owns 86,312 shares of the company’s stock, valued at approximately $3,262,593.60. The disclosure for this sale can be found here. Insiders sold 120,515 shares of company stock valued at $4,570,131 over the last quarter. Insiders own 12.30% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.